A phenanthrene derived PARP inhibitor is an extra-centrosomes de-clustering agent exclusively eradicating human cancer cells

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Castiel, Asher ^b   Visochek, Leonid ^a   Mittelman, Leonid ^a   Dantzer, Françoise ^c   Izraeli, Shai ^a,b   Cohen Armon, Malka ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c Centre National de la Recherche Scientifique Université de Strasbourg   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4H THIENO[2,3 C]ISOQUINOLIN 5 ONE; 6(5H) PHENANTHRIDINONE; INIPARIB; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHENANTHRENE DERIVATIVE; UNCLASSIFIED DRUG; VELIPARIB; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; N (OXO 5,6 DIHYDROPHENANTHRIDIN 2 YL) N,N DIMETHYLACETAMIDE HYDROCHLORIDE; N-(OXO-5,6-DIHYDROPHENANTHRIDIN-2-YL)-N,N-DIMETHYLACETAMIDE HYDROCHLORIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ARTICLE; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; CENTROSOME; COLON CANCER; CONTROLLED STUDY; CYTOLOGY; CYTOTOXICITY; DRUG DETERMINATION; DRUG MECHANISM; DRUG STRUCTURE; ENDOTHELIUM CELL; EPITHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LUNG CANCER; MESENCHYME CELL; OVARY CANCER; PANCREAS CANCER; TREATMENT RESPONSE; CELL CYCLE CHECKPOINT; CELL SURVIVAL; CHROMOSOME SEGREGATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; MITOSIS; MITOSIS SPINDLE; NEOPLASM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL SURVIVAL; CENTROSOME; CHROMOSOME SEGREGATION; ENZYME INHIBITORS; HUMANS; MITOSIS; MITOTIC SPINDLE APPARATUS; NEOPLASMS; PHENANTHRENES; POLY(ADP-RIBOSE) POLYMERASES;

EID: 80053343176     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-412     Document Type: Article

References (45)

1. Inbar-Rozensal D, Castiel A, Visochek L, Kastel D, Dantzer F, Izraeli S, Cohen-Armon M. A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors. Breast Canc Res 2009, 11/6/R78:1-11. 2815540, 19891779.
2. Chiarugi A, Meli E, Calvani M, Picca R, Picca R, Baronti R, Camaioni E, et al. Novel isoquinolinone-derived inhibitors of polyADP-ribose polymerase-1: Pharmacological characterization and neuroprotective effects in an in-vitro model of cerebral ischemia. J Pharmacol Exp Ther 2003, 305:943-949. 10.1124/jpet.103.048934, 12606624.
3. Jagtap P, Szabo C. Poly(ADP-ribose)polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discovery 2005, 4:421-440.
4. Gergely F, Basto R. Multiple centrosomes: together they stand, divided they fall. Genes Dev 2008, 22:2291-2296. 10.1101/gad.1715208, 2749672, 18765784.
5. Godinho SA, Kwon M, Pellman D. Centrosomes and cancer: how cancer cells divide with too many cetrosomes. Canc Met Rev 2009, 28:85-98.
6. Doxsey S. Re-evaluating centrosome function. Nat Rev Mol Cell Biol 2001, 2:688-698. 10.1038/35089575, 11533726.
7. Walczak CE, Heald R. Mechanisms of mitotic spindle assembly and function. International Rev of Cytology 2008, 265:111-158. (Elsevier Inc.).
8. Bettencourt-Dias M, Glover D. Centrosome biogenesis and function: centrosomics brings new understandings. Nat Rev Mol Cell Biol 2007, 8(6):451-463. doi:10.1038/nrm2180, 17505520.
9. Cunha-Ferreira I, Bento I, Bettencourt-Dias M. From zero to many: control of centriole number in development and disease. Traffic 2009, 10:482-498. 10.1111/j.1600-0854.2009.00905.x, 19416494.
10. Galimberti F, Thompson SL, Ravi S, Compton D, Dmitrovsky E. Anaphase Catastrophe Is a Target for Cancer Therapy. Clin Cancer Res 2011, 17:1218-1222. 10.1158/1078-0432.CCR-10-1178, 21288923.
11. Tsou M-FB, Stearns T. Controlling centrosome number: licenses and blocks. Cur Opin Cell Biol 2006, 18:74-78.
12. Leber B, Maier B, Fuchs F, Chi J, Riffel P, Anderhub S, Wagner L, Ho AD, Salisbury JL, Boutros M, Krämer A. Proteins Required for Centrosome Clustering in Cancer Cells. Sci Transl Med 2010, 2(33). DOI: 10.1126/scitranslmed.3000915, 20505215.
13. Cohen-Armon M, Visochek L, Rozensal D, Kalal A, Geistrikh I, Klein R, Bendetz-Nezer S, Yao Z, Seger R. DNA-independent PARP-1 activation by phosphorylated ERK2 increases Elk1 activity: a link to histone acetylation. Mol Cell 2007, 25:297-308. 10.1016/j.molcel.2006.12.012, 17244536.
14. Stearns T, Evans L, Kirschner M. γ-Tubulin is a highly conserved component of the centrosome. Cell 1991, 65:825-836. 10.1016/0092-8674(91)90390-K, 1840506.
15. Vayssiere JL, Petit PX, Risler Y, Mignotte B. Commitment to apoptosis is associated with changes in mitochondrial biogenesis and activity in cell lines conditionally immortalized with simian virus 40. Proc Natl Acad Sci USA 1994, 91:11752-11756. 10.1073/pnas.91.24.11752, 45310, 7972136.
16. Rieder CL, Maiato H. Stuck in Division or Passing through: What Happens When Cells Cannot Satisfy the Spindle Assembly Checkpoint. Dev Cell 2004, 7:637-651. 10.1016/j.devcel.2004.09.002, 15525526.
17. Kwon M, Godinho SA, Chandhok NS, Ganem NJ, Azioune A, Thery M, Pellman D. Mechanisms to suppress multipolar divisions in cancer cells with extra centrosomes. Genes Dev 2008, 22:2189-2203. 10.1101/gad.1700908, 2518815, 18662975.
18. Rouleau M, Patel A, Hendze MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nature Rev Cancer 2010, 10:293-301.
19. Krishnakumar R, Kraus WL. The PARP side of the nucleus: Molecular actions, physiological outcomes, and clinical targets. Mol Cell 2010, 39:8-24. 10.1016/j.molcel.2010.06.017, 2923840, 20603072.
20. Chang W, Dynek JN, Smith S. NuMA is a major acceptor of poly(ADP-ribosyl)ation by tankyrase 1 in mitosis. Biochem J 2005, 391:177-184. 10.1042/BJ20050885, 1276914, 16076287.
21. Chang P, Jacobson MK, Mitchison TJ. PolyADP-ribose is required for spindle assembly and structure. Nature 2004, 432:645-649. 10.1038/nature03061, 15577915.
22. Earl E, Saxena A, MacDonald A, Hudson DF, Shaffer LG, et al. PolyADP-ribose polymers at active centromers and neocentromers at metaphase. Hum Mol Gen 2000, 9:187-194. 10.1093/hmg/9.2.187, 10607829.
23. Saxena A, Saffery R, Wong LH, Kalitsis P, Choo A. Centromere Proteins Cenpa, Cenpb, and Bub3 Interact with Poly(ADP-ribose) Polymerase-1 Protein and Are Poly(ADP-ribosyl)ated. J Biol Chem 2002, 277:26921-26926. 10.1074/jbc.M200620200, 12011073.
24. Kanai M, Tong WM, Sugihara E, Wang ZQ, Fukasawa K, Miwa1 M. Involvement of Poly(ADP-Ribose) Polymerase 1 and Poly(ADP-Ribosyl)ation in Regulation of Centrosome function. Mol Cell Biol 2003, 23:2451-2462. 10.1128/MCB.23.7.2451-2462.2003, 150716, 12640128.
25. Ogino H, Nozaki T, Gunji A, Maeda M, Suzuki H, Ohta T, Murakami Y, Nakagama H, Sugimura T, Masutani M. Loss of Parp-1 affects gene expression profile in a genome-wide manner in ES cells and liver cells. BMC Genomics 2007, 8:41. 10.1186/1471-2164-8-41, 1810537, 17286852.
26. Coombs MM, Bhatt TS, Croft CJ. Correlation between carcinogenicity and chemical structure in Cyclopenta[α]- phenanthridines. Canc Res 1973, 33:832-837.
27. Phillips SD, Castle RN. A review of the chemistry of the antitumor benzo-[c]phenanthridine alkaloids nitidine and fagaronine and of the related antitumor alkaloid coralyne. Journal of Heterocyclic Chemistry 1981, 18:223-232.
28. Turchi G, Glatt HR, Seidel A, Puliti A, Sbrana I. Structure activity relationship in the induction of chromosomal aberrations and spindle disturbances in Chinese hamster epithelial liver cells by regioisomeric phenanthridine quinines. Cell Biology and Toxicology 1997, 13:155-165. 10.1023/A:1007302111081, 9088625.
29. Lamoral-Theys D, Andolfi A, Van Goietsenoven G, Cimmino A, Le Calve B, Wauthoz N. Lycorine, the main phenanthridine Amaryllidaceae alkaloid, exhibits significant antitumor activity in cancer cells that display resistance to proapoptotic stimuli: an investigation of structure-activity relationship and mechanistic insight. J Med Chem 2009, 52:6244-6256. 10.1021/jm901031h, 19788245.
30. Iwasaki H, Okabe T, Takara K, Toda T, Shimatani M, Oku H. Tumor-selective cytotoxicity of benzo[c] phenanthridine derivatives from Toddalia asiatica Lam. Cancer Chemother Pharmacol 2010, 65:719-726. 10.1007/s00280-009-1077-7, 19629483.
31. Ingle WL, Salisbury JL. The role of the centrosomes in the development of malignant tumors. Current topics in Dev Biol 1999, 49:313-329.
32. Ganem NJ, Godunov SA, Pellman D. A mechanism linking extra centrosomes to chromosomal instability. Nature 2009, 460:278-282. 10.1038/nature08136, 2743290, 19506557.
33. Fukasaw K. Oncogenes and tumour suppressors take in centrosomes. Nature Rev/Cancer 2007, 7:911-924.
34. Fielding AB, Lim S, Montgomery K, Dobreva I, Dedhar S. critical role of integrin-linked kinase, ch-TOG and TACC3 in centrosome clustering in cancer cells. Oncogene 2011, 30:521-534. 10.1038/onc.2010.431, 20838383.
35. Galimberti F, Thompson SL, Liu X, Li H, Memoli V, et al. Targeting the Cyclin E-Cdk-2 Complex Represses Lung Cancer Growth by Triggering Anaphase Catastrophe. Clin Canc Res 2010, 16:109-120.
36. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004, 4:253-265. 10.1038/nrc1317, 15057285.
37. Chen JG, Horwitz SB. Differential mitotic responses to microtubule-stabilizing and de-stabilizing drugs. Cancer Res 2002, 62:1935-1938.
38. Rebacz B, Larsen TO, Clausen MH, Rønnest MH, Löffler H, Ho AD, Krämer A. Identification of Griseofulvin as an inhibitor of centrosomal clustering in a phenotype-based screen. Canc Res 2007, 67:6342-6350.
39. Jackson JR, Denis R, Patrick DR, Mohammed M, Dar MM, Huang PS. Targeted anti-mitotic therapies: can we improve on tubulin agents?. Nature Rev Cancer 2007, 7:107-117.
40. Kozielski F, DeBonis S, Skoufias DA. Screening for inhibitors of microtubule-associated motor proteins. Methods Mol Med 2007, 137:189-207. 10.1007/978-1-59745-442-1_14, 18085231.
41. Manning JA, Kuma S. A potential role for NEDD1 and the centrosome in senescence of mouse embryonic fibroblasts. Cell Death Dis 2010, 1:e35. 10.1038/cddis.2010.12, 3032305, 21364642.
42. Riffell JL, Janicke RU, Roberge M. Caspase-3-Dependent Mitotic Checkpoint Inactivation by the Small-Molecule Inducers of Mitotic Slippage SU6656 and Geraldol. Mol Cancer Ther 2011, 10:839-849. 10.1158/1535-7163.MCT-10-0909, 21441410.
43. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, et al. Mutations of the B-RAF gene in human cancer. Nature 2002, 417:949-954. 10.1038/nature00766, 12068308.
44. Bild AH, Potti A, Nevins JR. Linking oncogenic pathways with therapeutic opportunities. Nat Rev Cancer 2006, 6:734-741.
45. O'Connor MJ, Martin NM, Smith GC. Targeted cancer therapies based on the inhibition of DNA strand break repair. Oncogene 2007, 26:7816-7824. 10.1038/sj.onc.1210879, 18066095.